5-Azacytidine: A New Active Agent for the Treatment of Acute Leukemia-Reference-Cited by-同舟云学术

5-Azacytidine: A New Active Agent for the Treatment of Acute Leukemia

Published:1973-09-01 Issue:3 Volume:42 Page:359-365
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Karon Myron¹²,Sieger Lance¹³,Leimbrock Suzanne¹⁴,Finklestein Jerry Z.¹⁵,Nesbit Mark E.¹⁶,Swaney Jerry J.¹⁷

Affiliation:

1. Division of Hematology, Department of Pediatrics, Childrens Hospital of Los Angeles. and the USC School of Medicine; Department of Pediatrics, Harbor General Hospital, and the UCLA School of Medicine, Torrance, Calif.; the Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, Minn.; and Childrens Memorial Hospital and the Department of Pediatrics, Northwestern Univers

2. Division of Hematology, Childrens Hospital of Los Angeles, Los Angeles, Calif.; Scholar, Leukemia Society of America.

3. Division of Hematology, Childrens Hospital of Los Angeles, Los Angeles. Calif 90027

4. Division of Hematology, Childrens Hospital of Los Angeles. Los Angeles, Calif 90027.

5. Pediatric Hematology. Harbor General Hospital, Torrance, Calif.

6. University of Minnesota School of Medicine, Minneapolis, Minn.

7. Childrens Memorial Hospital and the Department of Pediatrics, Northwestern University, Chicago, Ill.

Abstract

Abstract Thirty-seven children with acute leukemia were treated with 5-azacytidine in 5-day courses given every 14 days. Six out of 14 children with acute myelogenous leukemia who were adequately treated achieved an M1 marrow. Five of these subsequently developed complete remissions lasting 8 mo, 6 mo, 3 mo, 2 mo, and 2 mo. Of 22 children with acute lymphocytic leukemia, one achieved an M1 marrow and one an M2 marrow. The former attained a complete remission which lasted 3 mo. The maximum tolerated dose is between 150 to 200 mg/sq m on a daily x 5 schedule given every 14 days. The impressive activity of 5-aza-C in patients with acute myelogenous leukemia resistant to cytosine arabinoside indicates that this drug will become an important addition to the therapeutic armamentaria against this type of leukemia.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/42/3/359/578205/359.pdf

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The oncogenic gamma herpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) hijack retinoic acid-inducible gene I (RIG-I) facilitating both viral and tumour immune evasion;Tumour Virus Research;2022-12

2. Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia;Frontiers in Oncology;2022-07-12

3. Advances in Therapeutic L-Nucleosides and L-Nucleic Acids with Unusual Handedness;Genes;2021-12-24

4. 6,N2-Diaryl-1,3,5-triazine-2,4-diamines: synthesis, antiproliferative activity and 3D-QSAR modeling;RSC Advances;2020

5. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia;Cancer Drug Resistance;2020